NCT07352254

Brief Summary

The significance of the Post-COVID Syndrome (PCS) has been widely acknowledged. Various efforts are made to find out about the pathomechanisms behind PCS and to establish therapies. One sub-group of PCS-patients, however, is generally excluded from any studies, and that are those who are unable to visit outpatient clinics or hospitals for diagnostic work up or participation in clinical trials, as they are unable to leave their home and to seek medical support on their own physical and mental capabilities. They are housebound, mostly or totally bedridden. Similar cases are known from myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) of any cause and are graded as moderate to very severe ME/CFS according to the Canadian Consensus criteria. The patients are usually seen by their family doctor and have no access to medical specialists. The planned project aims to find out about the prevalence of this most severe manifestation of PCS, the clinical characteristics, the prevalence of mimics, risk factors and impact of the disease on the patients' life and their family/caregivers. Individual care and treatment plans will be developed and the effect of monthly consultation hours for patients and caregivers upon the patients' health status and the caregiver burden will be evaluated in a randomized controlled trial. The project will be performed in close cooperation between patients, caregivers, the patient's family doctor and a board of experts from internal medicine, neurology, psychosomatic medicine and general medicine at Hannover Medical School. We expect an improvement of the patients' and caregivers wellbeing with intensified medical care. We are aware, however, that intensification of the patient-doctor interaction carries the risk to exacerbate the patients' symptoms. The results of our study will show how current models of care for PCS and ME/CFS patients should be modified to fit to the individual patient's aims and capacities.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
32mo left

Started Jan 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress12%
Jan 2026Dec 2028

Study Start

First participant enrolled

January 1, 2026

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

January 11, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 20, 2026

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2028

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Last Updated

January 21, 2026

Status Verified

January 1, 2026

Enrollment Period

2.8 years

First QC Date

January 11, 2026

Last Update Submit

January 18, 2026

Conditions

Keywords

ME/CFShouseboundhouse call

Outcome Measures

Primary Outcomes (1)

  • Short Form (SF)-36 health survey, physical score

    Short-Form (SF-36) health survey to assess health related quality of life, here the physical score. Higher values indicate better health status. The range depends on age, gender and education.

    1 year

Study Arms (2)

intensified medical care

EXPERIMENTAL

monthly online visit in addition to standard care

Other: online visit

standard care

ACTIVE COMPARATOR

standard care as decided after discussion between family doctor and visiting specialists

Other: No Interventions

Interventions

monthly online visits

intensified medical care

No Interventions

standard care

Eligibility Criteria

Age18 Years - 69 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ME/CFS according to the Canadian Consensus Criteria
  • Bell Score ≤ 30
  • Duration of the postexertional malaise (PEM) \> 14 hours
  • Age \> 18 years and \< 70

You may not qualify if:

  • \- Pre-existing conditions or comorbidities that have (or could have) led to a restriction of mobility or mental capacity, such as various diseases of the central nervous system.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hannover Medical School

Hanover, 30625, Germany

RECRUITING

Related Publications (5)

  • Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980 Dec;20(6):649-55. doi: 10.1093/geront/20.6.649. No abstract available.

  • Braun M, Scholz U, Hornung R, Martin M. The burden of spousal caregiving: a preliminary psychometric evaluation of the German version of the Zarit burden interview. Aging Ment Health. 2010 Mar;14(2):159-67. doi: 10.1080/13607860802459781.

  • Morfeld M, Kirchberger I, Bullinger M. SF-36- Fragebogen zum Gesundheitszustand, 2. Auflage, Hogrefe Verlag, 2011

    RESULT
  • Sommerfelt K, Schei T, Angelsen A. Severe and Very Severe Myalgic Encephalopathy/Chronic Fatigue Syndrome ME/CFS in Norway: Symptom Burden and Access to Care. J Clin Med. 2023 Feb 13;12(4):1487. doi: 10.3390/jcm12041487.

  • Keith RA, Granger CV, Hamilton BB, Sherwin FS. The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil. 1987;1:6-18. No abstract available.

MeSH Terms

Conditions

Fatigue Syndrome, Chronic

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesEncephalomyelitisNeuroinflammatory DiseasesNervous System DiseasesNeuromuscular DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Meike Dirks, MD

    Hannover Medical School

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Karin Weissenborn, Professor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant, Department of Neurology, Principal Investigator

Study Record Dates

First Submitted

January 11, 2026

First Posted

January 20, 2026

Study Start

January 1, 2026

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

December 1, 2028

Last Updated

January 21, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

It is planned to share the data with the registry of the outpatient clinic for rare diseases at MHH

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
The IPD and supporting information will be available after final data analysis for ACCESS for at least 10 years
Access Criteria
Anonymous data will be available for scientific purposes after reasonable request

Locations